Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing ...
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) ...
TAMPA, Fla. and LONDON, April 27, 2026 (GLOBE NEWSWIRE)-- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall ...
The modulation of RNA splicing by small molecules has emerged as a promising strategy for treating pathogenic infections, human genetic diseases, and cancer; however, the principles by which splicing ...
Akari Therapeutics (AKTX) announced on Thursday the pricing of a private placement financing round, expecting to raise an aggregate of approximately $5.5M in gross proceeds. With these funds, the ...
Cancers driven by hiccups in RNA processing can’t hide from our immune system, according to new work published today in Cell. A cross-institutional team Fred Hutch Cancer Center and Memorial Sloan ...
Spinal muscular atrophy, or SMA, is the leading genetic cause of infant death. Less than a decade ago, Cold Spring Harbor Laboratory (CSHL) Professor Adrian Krainer showed this brutal disease can be ...
RNA splicing is a cellular process that is critical for gene expression. After genes are copied from DNA into messenger RNA, portions of the RNA that don't code for proteins, called introns, are cut ...
TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancerApproval strengthens Akari’s global intellectual property ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results